CASI Pharmaceuticals Inc (CASI) focuses on the development and commercialization of therapeutic and pharmaceutical products for the treatment of cancer and other unmet medical needs with a primary focus on greater China. The company focuses on hematology-oncology diseases and has launched products such as EVOMELA (Melphalan for Injection) and FOLOTYN (Pralatrexate) in China. CASI Pharmaceuticals engages in acquiring, developing, and commercializing products that address unmet medical needs, particularly in the areas of hematology oncology, autoimmune diseases, and organ transplant rejection. The company has built an infrastructure in China that includes sales and marketing, medical affairs, regulatory and clinical development, and manufacturing capabilities.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

CASI is actively engaged in research and development initiatives focused on developing and commercializing innovative therapeutics, particularly in the hematology/oncology field. The company's R&D efforts include compensation and expenses related to research personnel, research collaborations, and costs associated with pre-clinical testing and clinical trials of product candidates. CASI Pharmaceuticals Inc. is developing CID-103, an anti-CD38 monoclonal antibody, for the treatment of organ transplant rejection and autoimmune diseases. The company is also involved in the development of other pipeline products such as EVOMELA, FOLOTYN, CNCT19, and CB-5339. The company has entered into agreements to acquire equity interests in other entities to support its R&D activities and has divested certain regional rights to focus on its strategic priorities. The company has established CASI China, headquartered in Beijing with an office in Shanghai, as a key R&D unit. CASI China also engages in business development activities and executive management, with global management decisions primarily made out of this unit. In FY2025, the company spent US$6.2 million on its R&D activities, which as a percentage of revenue stood at 29.9%.